Imagyn Medical Inc.: Building a Market Franchise in Women's Health
Imagyn faces problems common to small device companies: a daunting FDA, less lucrative end-markets, and lack of effective distribution. Short-term it’s betting on US Surgical to market its products. Longer-term it hopes to grow by building a portfolio of products that move gynecological and infertility procedures out of the hospital.
You may also be interested in...
908 Devices, Zimmer Biomet and Ortho Clinical Diagnostics have all appointed new directors, Biolase promotes executive vice president to chief executive officer role, and more.
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."